华森制药 (002907.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	800.0M	827.1M	774.8M	691.5M	785.2M
Cost of Revenue	339.9M	352.5M	331.1M	311.3M	319.3M
Gross Profit	460.1M	474.7M	443.8M	380.2M	465.9M
Operating Expenses
R&D Expense	96.9M	89.8M	59.1M	78.1M	58.8M
SG&A Expense	—	—	—	—	—
General & Admin Expense	65.2M	63.9M	57.8M	53.1M	46.6M
Selling & Marketing Expense	245.6M	254.7M	250.5M	210.7M	245.9M
Other Expenses	—	—	—	—	—
Total Operating Expenses	415.8M	415.3M	368.8M	344.2M	366.6M
Cost and Expenses	755.7M	767.8M	699.8M	655.6M	685.9M
Operating Income (EBIT)	82.1M	94.0M	93.8M	45.8M	108.8M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	65.8M	77.5M	93.4M	42.8M	108.2M
Income Tax Expense	22.0M	22.2M	16.7M	10.1M	9.8M
Bottom Line
Net Income	57.5M	65.1M	76.7M	32.7M	98.4M
Earnings from Cont. Ops	43.8M	55.2M	76.7M	32.7M	98.4M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	57.5M	65.1M	76.7M	32.7M	98.4M
Per Share
Basic EPS	CN¥0.14	CN¥0.16	CN¥0.18	CN¥0.08	CN¥0.24
Diluted EPS	CN¥0.14	CN¥0.16	CN¥0.18	CN¥0.08	CN¥0.24
Revenue Per Share	CN¥1.92	CN¥1.98	CN¥1.85	CN¥1.66	CN¥1.95
Shares
Basic Shares Outstanding	417.7M	417.5M	417.7M	417.6M	403.1M
Diluted Shares Outstanding	417.7M	417.5M	417.7M	417.6M	403.1M
Profitability Metrics
EBITDA	—	184.8M	183.1M	129.0M	184.5M
D&A	—	90.8M	89.3M	83.2M	75.6M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026